Table S5.

Cumulative incidences for liver-related morbidity among all patients at risk after SVR, after non-SVR, and among untreated patients, with death and LTx as competing risks

Morbidity	All patients, % (95% CI)	After SVR, % (95% CI)	After non-SVR, % (95% CI)	Untreated time, % (95% CI)
HCC, 1-year	1.35 (0.62–2.08)	0.48 (0–1.41)	2.55 (0.68–4.42)	1.28 (0.33–2.23)
HCC, 5-year	9.14 (7.08–11.2)	5.38 (1.87–8.88)	13.25 (8.65–17.85)	9.79 (6.45–13.12)
HCC, 10-year	18.3 (14.88–21.71)	6.38 (2.39–10.37)	26.16 (18.7–33.62)	18.99 (13.19–24.8)
Decompensation, 1-year	5.2 (3.65–6.76)	1.50 (0–3.19)	3.91 (1.53–6.29)	7.57 (4.95–10.19)
Decompensation, 5-year	15.79 (13–18.6)	5.58 (1.95–9.21)	19.25 (13.67–24.84)	20.86 (15.65–26.07)
Decompensation, 10-year	28.23 (23.97–32.48)	6.64 (2.5–10.79)	34.69 (26.5–42.89)	36.12 (27.9–44.34)

Note: Death and LTx were treated as competing risks.

Abbreviations: SVR, sustained virologic response (24 weeks after end of treatment); LTx, liver transplantation; HCC, hepatocellular carcinoma.